08/07/2025
The treatment landscape for Parkinson’s Disease is changing.
Read more to enhance your knowledge of Parkinson’s Disease and its management! https://bit.ly/44wEx8j
Indication: CREXONT® (carbidopa and levodopa) extended release capsules for oral use is indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults.
CREXONT may cause falling asleep during activities of daily living, somnolence, or dizziness. The most common side effects are nausea and anxiety. See Indication and Prescribing Info on: bit.ly/4lbamdB